Daihan Pharmaceutical Co.Ltd (023910) — Capital Reinvestment Ratio
Daihan Pharmaceutical Co.Ltd (023910) has a Capital Reinvestment Ratio of 1.14x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩9.47 Billion) in capital expenditures (₩10.79 Billion). See how much free cash does Daihan Pharmaceutical Co.Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Daihan Pharmaceutical Co.Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Daihan Pharmaceutical Co.Ltd's Capital Reinvestment Ratio across 11 annual periods.
Annual Capital Reinvestment Ratio for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Daihan Pharmaceutical Co.Ltd from 2014 to 2024. For live market cap and broader valuation context, see how much is Daihan Pharmaceutical Co.Ltd worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.44x | ₩35.64 Billion | ₩15.80 Billion | ▼ -19.0% |
| 2023 | 0.55x | ₩38.86 Billion | ₩21.28 Billion | ▲ +84.2% |
| 2022 | 0.30x | ₩29.00 Billion | ₩8.62 Billion | ▲ +1.9% |
| 2021 | 0.29x | ₩40.62 Billion | ₩11.85 Billion | ▲ +83.0% |
| 2020 | 0.16x | ₩33.63 Billion | ₩5.36 Billion | ▼ -67.5% |
| 2019 | 0.49x | ₩35.26 Billion | ₩17.30 Billion | ▼ -52.8% |
| 2018 | 1.04x | ₩44.94 Billion | ₩46.69 Billion | ▲ +1.0% |
| 2017 | 1.03x | ₩20.45 Billion | ₩21.05 Billion | ▲ +31.2% |
| 2016 | 0.78x | ₩27.92 Billion | ₩21.90 Billion | ▲ +255.8% |
| 2015 | 0.22x | ₩17.98 Billion | ₩3.96 Billion | ▼ -80.0% |
| 2014 | 1.10x | ₩9.48 Billion | ₩10.47 Billion | — |